Fatih M. Uckun, M.D., Ph.D

Fatih M. Uckun, M.D., Ph.D Email and Phone Number

Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer; @ Ares Pharmaceuticals, LLC
Beverly Hills, CA, US
Fatih M. Uckun, M.D., Ph.D's Location
Beverly Hills, California, United States, United States
Fatih M. Uckun, M.D., Ph.D's Contact Details

Fatih M. Uckun, M.D., Ph.D work email

Fatih M. Uckun, M.D., Ph.D personal email

n/a
About Fatih M. Uckun, M.D., Ph.D

Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO, ASH and AACR. Dr. Uckun is a Principal Member of the Turkish Academy of Sciences/TUBA (a Member of the European Federation of Academies of Sciences and Humanities/ALLEA and Association of Academies and Societies of Sciences in Asia/AASSA). He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and NIH grant review/special emphasis panels.In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. He served as a Defense Advanced Research Projects Agency (DARPA) PI and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons. https://www.researchgate.net/profile/Fatih_Uckunhttps://loop.frontiersin.org/people/679873/biohttps://orcid.org/0000-0001-9334-183Xhttps://sciprofiles.com/profile/fatihuckun

Fatih M. Uckun, M.D., Ph.D's Current Company Details
Ares Pharmaceuticals, LLC

Ares Pharmaceuticals, Llc

View
Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer;
Beverly Hills, CA, US
Employees:
3
Fatih M. Uckun, M.D., Ph.D Work Experience Details
  • Ares Pharmaceuticals, Llc
    Head Of Immuno-Oncology And Chief Medical And Chief Scientific Officer;
    Ares Pharmaceuticals, Llc
    Beverly Hills, Ca, Us
  • Ares Pharmaceuticals, Llc
    Head Of Immuno-Oncology And Chief Medical/Chief Scientific Officer;
    Ares Pharmaceuticals, Llc Jul 2015 - Present
    St. Paul And Beverly Hills, Us
  • Aresmit Biomedical Computational Strategies (A.B.C.S)
    Head Of Strategy For Clinical Development And Translational Hematology-Oncology
    Aresmit Biomedical Computational Strategies (A.B.C.S) Jan 2017 - Present
    Minneapolis, Minnesota, Us
  • Oncotelic
    Chief Medical Officer/Advisor
    Oncotelic May 2022 - Feb 2023
    Agoura Hills, California, Us
    https://www.oncotelic.com/about-us/
  • Reven Pharmaceuticals
    Exec Vice President, Global Head Of Clinical And Medical Affairs; Chief Medical & Scientific Officer
    Reven Pharmaceuticals Jun 2020 - Mar 2022
    Westminster, Colorado, Us
    As Executive Vice President, Clinical Affairs, Global Head of Clinical and Medical Affairs, and Chief Scientific Officer, Dr. Uckun’s responsibilities include providing medical-scientific leadership and direction for Reven’s pipeline of clinical development programs in sepsis, metabolic disorders, inflammatory disorders, including but not limited to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH), iatrogenic organ toxicity, including chemotherapy-induced liver toxicity, and translational oncology as well as contributing to the strategy, direction and execution of the company's clinical development plans. Dr. Uckun will coordinate collaborations with academic centers and other biotech and pharmaceutical companies and provide day-to-day oversight for internal research, research and development, regulatory, safety as well as clinical operations teams.
  • Aptevo Therapeutics Inc
    Consultant; Chief Clinical Advisor
    Aptevo Therapeutics Inc Mar 2021 - Dec 2021
    Seattle, Wa, Us
    As a consultant to the Aptevo leadership, Dr. Uckun provides subject matter expertise in design of patient-centric clinical trials in acute leukemia patients. In collaboration with other leukemia experts at academic health centers in the US and Europe, he contributes to the design of clinical research protocols to evaluate Aptevo's bispecific antibodies as components of innovative multi-modality regimens that may improve the outcome of adult and pediatric acute leukemia patients.
  • Worldwide Clinical Trials
    Vice President And Clinical Strategy Lead, Oncology-Hematology, Member Of Covid-19 Task Force
    Worldwide Clinical Trials Jan 2020 - Jun 2020
    Research Triangle Park, Nc, Us
  • Oncotelic, Inc.
    Chief Medical Officer
    Oncotelic, Inc. Jan 2019 - Jan 2020
    http://oncotelic.com/management/
  • Mateon Therapeutics
    Chief Medical Officer
    Mateon Therapeutics Jan 2019 - Jan 2020
    South San Francisco, Ca, Us
    In April 2019. Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. have completed their merger and created a new immuno-oncology company with a late-stage clinical asset against cancer and a promising product pipeline. In connection with the merger, Oncotelic, Inc. has become a wholly owned subsidiary of Mateon, with the former Oncotelic shareholders receiving a combination of common and preferred stock in Mateon representing approximately 85% of Mateon’s outstanding equity. Mateon’s prior stockholders retain approximately 15% of the outstanding equity.
  • Syneos Health (Previously Inc Research/Inventiv Health)
    Executive Medical Director, Global Oncology & Hematology
    Syneos Health (Previously Inc Research/Inventiv Health) Sep 2017 - Nov 2018
    Morrisville, Nc, Us
    Function as a senior strategy advisor in Clinical Development, Global Oncology and Hematology with an emphasis on advanced solid tumors and relapsed or therapy-refractory hematologic malignanciesContribute to design of clinical path for small molecules as well as biologics with an emphasis on immuno-oncology drugs. Contribute to regulatory strategy for clinical development of multiple drug candidates, including targeted therapeutics, therapeutic vaccines, immuno-modulators, cytotoxic agents, immuno-oncology drugs. Contribute to biomarker identification and design of biomarker-guided clinical trialshttps://www.syneoshealth.com/
  • University Of Southern California
    Professor
    University Of Southern California Jul 2009 - Jun 2015
    Los Angeles, Ca, Us
    Professor of Research Pediatrics, Department of Pediatrics at USC Keck School of MedicineMember, Developmental Therapeutics Program, Norris Comprehensive Cancer Center
  • University Of Southern California
    Principal Investigator; Usc Stem Cell Regenerative Medicine Initiative
    University Of Southern California Jul 2013 - May 2015
    Los Angeles, Ca, Us
    Hematopoietic stem cell research
  • University Of Southern California
    Member, Norris Comprehensive Cancer Center
    University Of Southern California Jan 2010 - May 2015
    Los Angeles, Ca, Us
    Translational cancer research
  • Children'S Hospital Los Angeles Chla
    Professor Research Pediatrics And Head, Translational Research In Leukemia And Lymphoma At The Cccbd
    Children'S Hospital Los Angeles Chla Jul 2009 - Jun 2015
    Los Angeles, Ca, Us
    Professor Research PediatricsHead, Translational Research in Leukemia and Lymphoma
  • Drug Discovery Enterprises (Dba Parker Hughes Institute)
    Director, Research (Also Served As The Founding President/Ceo Of Its Spin-Off Biotech Companies)
    Drug Discovery Enterprises (Dba Parker Hughes Institute) 1997 - 2008
    A 501(c)3 research organization that was formed to discover new drug candidates against cancer. Spin off companies included Alexander Parker Corporation, Paradigm Pharmaceuticals, Jupiter Research.
  • Paradigm Pharmaceuticals Llc
    President/Cso
    Paradigm Pharmaceuticals Llc Oct 2002 - Feb 2007
    Coordinated target validation, portfolio prioritization, and drug discovery/development efforts in oncology and infectious diseases.
  • Alexander Parker Corporation
    President/Cso
    Alexander Parker Corporation 1995 - 2000
    Coordinated the CRO function of the company for the Drug Discovery Enterprises, Inc(dba Parker Hughes Institute). Served as the lead FDA contact and IND Investigator-Sponsor for Phase 1, Phase 2 and randomized Phase 2 clinical trials of immuno-oncology products. Served as the lead contact for the Childrens Cancer Study Group for groupwide clinical testing of anti-CD19 immunoconjugates.Select references:Seibel NL, Sather H, Steinherz PG, De Laat C, Ettinger LJ, Freyer D, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL. Children's Cancer Group. Blood. 1961;2000;96:721a.Seibel NL, Krailo M, O'Neill K, Franklin J, Uckun F, Reaman GH. Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse, a Children's Cancer Group Study. Pediatric Research. 1999;45:5. Abstract 195.
  • University Of Minnesota
    Director Of Biotherapy Institute
    University Of Minnesota 1995 - 1997
    Minneapolis And St. Paul, Minnesota, Us
    Directed translational biotherapy research on immunoconjugates, monoclonal antibodies, fusion toxins, and cytokine-drug conjugates. Reported to Provost of Academic Health Center and coordinated clinical and laboratory research efforts funded by multiple NIH grants.
  • University Of Minnesota
    Full Professor (With Tenure)
    University Of Minnesota 1993 - 1997
    Minneapolis And St. Paul, Minnesota, Us
    Conducted research and patient care and education
  • University Of Minnesota
    Associate Professor (With Tenure)
    University Of Minnesota 1990 - 1992
    Minneapolis And St. Paul, Minnesota, Us
    Conducted research and patient care and education
  • University Of Minnesota
    Assistant Professor
    University Of Minnesota 1986 - 1989
    Minneapolis And St. Paul, Minnesota, Us
    Conducted research and patient care and education

Fatih M. Uckun, M.D., Ph.D Skills

Translational Research Public Speaking Cancer Immunology Clinical Research Cancer Research Cell Cell Biology Molecular Biology Drug Discovery Cell Culture Biotechnology Research Translational Medicine Medicine In Vivo Pediatrics Animal Models Assay Development Biochemistry Immunohistochemistry Pharmacology Clinical Development Stem Cells Oncology Monoclonal Antibodies Tissue Culture Laboratory Flow Cytometry Biomarkers R&d Drug Development Protein Chemistry Pediatric Hematology/oncology Clinical Supervision Clinical Study Design Clinical Monitoring Grant Writing Genetics Confocal Microscopy Medical Research In Vitro Lifesciences Neuroscience Drug Design Molecular Pharmacology Drug Testing Molecular And Cellular Biology Molecular Oncology Molecular Genetics Virology

Fatih M. Uckun, M.D., Ph.D Education Details

  • Heidelberg University
    Heidelberg University
    Internal Medicine
  • University Of Minnesota Medical School
    University Of Minnesota Medical School
    Pediatrics Residency; Fellowship In Hematology/Oncology; Postdoctoral Fellowship In Immunology/Bmt

Frequently Asked Questions about Fatih M. Uckun, M.D., Ph.D

What company does Fatih M. Uckun, M.D., Ph.D work for?

Fatih M. Uckun, M.D., Ph.D works for Ares Pharmaceuticals, Llc

What is Fatih M. Uckun, M.D., Ph.D's role at the current company?

Fatih M. Uckun, M.D., Ph.D's current role is Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer;.

What is Fatih M. Uckun, M.D., Ph.D's email address?

Fatih M. Uckun, M.D., Ph.D's email address is fm****@****ast.net

What is Fatih M. Uckun, M.D., Ph.D's direct phone number?

Fatih M. Uckun, M.D., Ph.D's direct phone number is +161281*****

What schools did Fatih M. Uckun, M.D., Ph.D attend?

Fatih M. Uckun, M.D., Ph.D attended Heidelberg University, University Of Minnesota Medical School.

What are some of Fatih M. Uckun, M.D., Ph.D's interests?

Fatih M. Uckun, M.D., Ph.D has interest in Children, Environment, Science And Technology, Disaster And Humanitarian Relief, Human Rights, Translational Research, Health.

What skills is Fatih M. Uckun, M.D., Ph.D known for?

Fatih M. Uckun, M.D., Ph.D has skills like Translational Research, Public Speaking, Cancer, Immunology, Clinical Research, Cancer Research, Cell, Cell Biology, Molecular Biology, Drug Discovery, Cell Culture, Biotechnology.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.